Back to top
more

Arena Pharmaceuticals, Inc. (ARNA)

(Delayed Data from NSDQ)

$47.60 USD

47.60
308,048

+1.62 (3.52%)

Updated May 3, 2019 04:00 PM ET

After-Market: $47.68 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Are Options Traders Betting on a Big Move in Arena (ARNA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Arena (ARNA) stock based on the movements in the options market lately.

Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.

Is a Beat Likely for Pfizer (PFE) This Earnings Season?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the fourth quarter.

Arena (ARNA) Stock Up in 6 Months on PFE Merger Deal & Pipeline

by Zacks Equity Research

Arena Pharmaceuticals' (ARNA) potential acquisition by Pfizer to enable it to advance the development of its pipeline, especially the company's lead candidate, etrasimod, for ulcerative colitis.

Kinjel Shah headshot

Here's Why Pfizer (PFE) Appears Strongly Placed for 2022

by Kinjel Shah

While the COVID vaccine should continue to boost Pfizer (PFE) revenues in 2022, Paxlovid is also likely to become an important top-line driver

Are Options Traders Betting on a Big Move in Arena (ARNA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Arena (ARNA) stock based on the movements in the options market lately.

Should You Buy Arena Pharmaceuticals, Inc. (ARNA) After Golden Cross?

by Zacks Equity Research

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Kinjel Shah headshot

Will Lilly and Pfizer be Top Pharma Stocks Again in 2022?

by Kinjel Shah

Among the large drugmakers, stocks of Pfizer (PFE) and Eli Lilly (LLY) rose significantly in 2021 in response to their pipeline progress.

The Zacks Analyst Blog Highlights: Pfizer, Arena Pharma, Merck, Jazz Pharm and Sanofi

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, Arena Pharma, Merck, Jazz Pharm and Sanofi

Company News for Dec 14, 2021

by Zacks Equity Research

Companies In The News Are: ARNA, PFE, LLY, FHTX, TPX, NAVI.

Kinjel Shah headshot

Does PFE, ARNA Deal Signal Robust Pharma M&A Activity in 2022?

by Kinjel Shah

The Pfizer (PFE)-Arena (ARNA) deal raises hopes that M&A activity will pick up significantly in 2022. as big drugmakers are sitting on huge piles of cash.

Pfizer (PFE) to Buy Arena, Boost Immuno-Inflammatory Pipeline

by Zacks Equity Research

Pfizer (PFE) signs an agreement to acquire Arena Pharmaceuticals for $6.7 billion in cash. Stock rises.

Arena (ARNA) Q3 Loss Wider Than Anticipated, Revenues Nil

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) misses Q3 bottom-line estimates. The company progresses with pipeline development.

Arena Pharmaceuticals, Inc. (ARNA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arena Pharmaceuticals, Inc. (ARNA) delivered earnings and revenue surprises of -32.64% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Arena Pharmaceuticals, Inc. (ARNA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Arena Pharmaceuticals, Inc. (ARNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M

by Zacks Equity Research

AzurRx BioPharma (AZRX) acquires First Wave Bio for $229 million. Following the acquisition, the company is set to rename itself as First Wave BioPharma.

Arena Pharmaceuticals, Inc. (ARNA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arena Pharmaceuticals, Inc. (ARNA) delivered earnings and revenue surprises of -8.60% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Arena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE

by Zacks Equity Research

The FDA bestows an Orphan Drug status to Arena's (ARNA) lead pipeline candidate, etrasimod, for the treatment of eosinophilic esophagitis.

Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel

by Zacks Equity Research

Arena (ARNA) is developing temanogrel in a phase II study as potential treatment for coronary microvascular obstruction in patients undergoing percutaneous coronary intervention.

Why Is Arena Pharmaceuticals, Inc. (ARNA) Down 2.8% Since Last Earnings Report?

by Zacks Equity Research

Arena Pharmaceuticals, Inc. (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Arena (ARNA) Q1 Earnings Beat Estimates, Etrasimod Progresses

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) beats Q1 bottom-line estimates. The company progresses with the development of its key pipeline candidate, etrasimod.

Arena Pharmaceuticals, Inc. (ARNA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arena Pharmaceuticals, Inc. (ARNA) delivered earnings and revenue surprises of 9.59% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?